In vitro cytotoxic activity of taxol' and taxotere on primary cultures and established cell lines of human ovarian cancer
Explore this paper's citation graph
Summary
A direct relationship was observed between the proliferative activity of the tumor cell population and response to Taxol and/or Taxotere.
- Type
- article
- Published
- 1993-01-01
- Cited by
- 16
- References
- 31
- OpenAlex
- https://openalex.org/W2056768409
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21483933
Keywords
Clonogenic assay, Cytotoxic T cell, Biology, Cell culture, Cisplatin
References
- Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms
- Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors.
- Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
- Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.
- Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture.
- Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue.
- In vitro assays for new drug screening: comparison of a thymidine incorporation assay with the human tumor colony-forming assay.
- An improved synthesis of the taxol side chain and of RP 56976
- Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of taxol and analogues
- Promotion of microtubule assembly in vitro by taxol
- Phase I trial of Taxotere: five-day schedule.
- Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.
- Reactivity of a monoclonal antibody with human ovarian carcinoma.
- Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.
- Phase I clinical and pharmacokinetic study of taxol.
- Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay.
- A phase I trial of taxol given by a 6-hour intravenous infusion.
- Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.
- Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay
- Chemotherapy in ovarian carcinoma: present role and future prospects.
Cited by
- Induction of apoptosis by taxol and cisplatin and effect on cell cycle-related proteins in cisplatin-sensitive and -resistant human ovarian cells.
- A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study.
- Paclitaxel-induced apoptosis in Jurkat, a leukemic T cell line, is enhanced by ceramide.
- Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer.
- In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers
- Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies
- Drug Evaluation: Oncologic, Endocrine & Metabolic: Docetaxel (Taxotere®): current status and clinical prospects
- Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo.
- Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.
- Docetaxel in the treatment of ovarian cancer.
- Cytotoxicity activities against cervical and skin cancer cell lines of Smilax kraussiana and Anthocleista rhizophoroides, two endemic species widely used in traditional medicine in Madagascar
- Sites of biosynthesis and storage of Taxol in Taxus media (Rehder) plants: Mechanism of accumulation.
- Drug-eluting stents.
- Coronary Arterial Drug-Eluting Stent: From Structure to Clinical
Related papers
- Sequence‐dependent antitumor activity of paclitaxel (taxol) and cisplatin in vivo
- Neuroprotective interactions in rats between paclitaxel and cisplatin.
- Clinical study of paclitaxel plus cisplatin in the treatment of recurrent cervical cancer
- Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro.
- Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).
- Phase I II T rial o f D oxorubicin, P aclitaxel, a nd t he Combination o f D oxorubicin a nd P aclitaxel a s F ront-Line Chemotherapy f or M etastatic B reast C ancer: An I ntergroup T rial ( E1193)
- Chemosensitivities of human clonogenic breast tumor cells.
- Molecular mechanisms of cisplatin resistance in ovarian cancer
- Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel
- Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label‐free LC/MS‐based protein quantification method